AUTHORS
Guillermo Montalban-Bravo, MD, Emma St Martin, MD2, Yuanxin Xi3, Yue Wei, PhD4, Kirbie Linthicum5, Kelly Sharon Chien, MD6, Ian Bouligny, M.D.7, Rashmi Kanagal-Shamanna, MD8, Alexandre Bazinet, MD9, Danielle Hammond, MD10, Alex Bataller, MD, PhD11, Courtney DiNardo, MD, MSCE12, Sa Wang, MD13, Keyur P. Patel, MD14, Carlos Bueso-Ramos, M.D., Ph.D.15, Raya Mawad16, Sioban Keel17, Terra Lasho, PhD18, Christy Finke, BS19, Aref Al-Kali, M.D.20, Cecilia Arana Yi, M.D.21, Clifford Csizmar, M.D., Ph.D.22, Kaaren Reichard, MD23, Rong He, MD24, Abhishek Avinash Mangaonkar, MBBS25, Yael Kusne, MD, PhD26, James Foran, FRCPC27, Jing Wang28, Guillermo Garcia-Manero, MD29, Sanam Loghavi, MD30, Mrinal M. Patnaik, MD, MBBS31
AFFILIATIONS
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
15 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
16 University of Washington, Seattle, Washington, United States
17 University of Washington, Seattle, Washington, United States
18 Mayo Clinic, Rochester, Minnesota, United States
19 Mayo Clinic, Rochester, Minnesota, United States
20 Mayo Clinic, Rochester, Minnesota, United States
21 Mayo Clinic, Rochester, Minnesota, United States
22 Mayo Clinic, Rochester, Minnesota, United States
23 Mayo Clinic, Rochester, Minnesota, United States
24 Mayo Clinic, Rochester, Minnesota, United States
25 Mayo Clinic, Rochester, Minnesota, United States
26 Mayo Clinic, Rochester, Minnesota, United States
27 Mayo Clinic, Rochester, Minnesota, United States
28 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
29 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
30 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
31 Mayo Clinic, Rochester, Minnesota, United States
ABSTRACT
Introduction: KRAS mutations are detected in 10-15% of patients (pts) with chronic myelomonocytic leukemia (CMML); however, they frequently represent late genomic events secondary to pre-existing ancestral clones. RAS-associated autoimmune leukoproliferative disorder (RALD) is a rare childhood hematologic disorder associated with isolated somatic KRAS mutations. Here we report a cohort of adult pts with KRAS-associated clonal monocytosis (KRAS-CM) with morphologic features overlapping with CMML but with a distinct natural history akin to that of RALD.
Methods: We studied 27 pts (MD Anderson n=14; Mayo Clinic n=13) with isolated KRAS mutations who otherwise met criteria for CMML and compared them to a control cohort of bona fide CMML pts with KRAS mutations (n=53). Next-generation sequencing was performed at diagnosis. Bone marrow (BM) CD34+ myeloid progenitors and monocytes were characterized by flow cytometry. We performed bulk RNA-sequencing (RNA-seq) of BM mononuclear cells (MNCs) from KRAS-CM (n=6) and CMML (n=6) pts and single-cell (sc) RNA-seq of BM MNCs from KRAS-CM (n=3), CMML pts (n=3) and healthy donors (HDs, n=3). Survival was censored at stem cell transplant (SCT) and evaluated using Kaplan-Meier or Cox proportional hazards methods.
Results: Compared to CMML, KRAS-CM pts were younger (58 vs 69 years, p<0.001), frequently female (56% vs 24%, p=0.006), and less likely to present with proliferative features (WBC³13x109/L; 22% vs 62%, p<0.001) or CMML-2 (0% vs 25%, p=0.005). Among KRAS-CM pts, 41% had morphologic dysplasia and 62% had MF-1/MF-2. Twenty-one (78%) pts had splenomegaly with 30%, 33% and 11% having lymphadenopathy, hepatomegaly or non-hepatosplenic extramedullary disease at diagnosis, respectively. Autoimmune (AI) disorders were observed in 70% of KRAS-CM pts including: immune cytopenias (n=6), arthritis (n=4), serositis (n=3), systemic lupus (n=1), antiphospholipid syndrome (n=1), multiple sclerosis (n=1), Sjögren’s disease (n=1), psoriasis (n=1), interstitial pneumonitis (n=1), rheumatoid arthritis (n=1), sarcoidosis (n=1) and Guillain-Barré syndrome (n=1). An aberrant CD34+ phenotype was observed in 27% of KRAS-CM pts. KRASG12D mutations were far more frequent in KRAS-CM than CMML (59% vs 9%, p<0.001). KRAS mutations in CMML, but not KRAS-CM, were topographically more diverse across multiple codons (e.g. G12, G13, A146, Q61, A59, T58). KRAS variant allele frequency was higher in KRAS-CM than CMML (42.5% vs 26.2%, p<0.0001) suggesting distinct ontogeny. Accordingly, clonal hierarchy analysis confirmed that KRAS mutations were subclonal in 43% of CMML pts, and co-dominant with SRSF2, TET2 or ASXL1 mutations in most others.
With a median follow-up of 26 months (95% CI 12-39 months), none of KRAS-CM pts progressed to AML, a striking difference compared to CMML (0% vs 19%, p=0.016), with KRAS-CM pts demonstrating a superior leukemia-free survival (161 months vs 28 months; HR 0.25, 95% CI 0.09-0.62, p=0.0031) and overall survival (161 months vs 30 months; HR 0.29, 95% CI 0.10-0.84, p=0.0226) in comparison to CMML pts. Causes of death among KRAS-CM pts included pneumonia (n=2), acute hypoxic failure (n=2) and bowel ischemia (n=1); the cause of death was unknown in 1 pt.
Bulk RNA-seq of BM MNCs revealed that KRAS-CM and CMML cases clustered separately by principal component analysis. KRAS-CM MNCs had higher expression of genes involved in inflammatory, interferon and inflammasome-associated pathways and lower expression of E2F targets and cell proliferation genes than CMML. sc-RNA-seq revealed that although both entities were characterized by monocyte expansion (mainly of CD14+ monocytes), KRAS-CM had lower frequencies of immature monocyte, progenitor and dendritic/plasmacytoid dendritic cell populations than CMML. KRAS-CM, but not CMML, preserved normal frequencies and cell-type distributions of the B cell lineage compared to HDs. KRAS-CM CD14+ monocytes (31% of cells) showed upregulation of interferon, inflammatory and NF-κB signaling compared to HDs. Mass cytometry by time of flight (CyTOF) of BM MNCs from KRAS-CM pts, HDs and CMML controls is underway to verify these findings at the protein level.
Conclusions: Although both KRAS-CM and CMML are defined by clonal monocytosis, our data suggest that KRAS-CM has unique biology associated with distinct clinical and genetic features and natural history that warrant its recognition as an entity independent of CMML.
DISCLOSURES
Guillermo Montalban-Bravo, MD: Solu Therapeutics - Research Funding; Rigel Pharmaceuticals - Research Funding; Takeda Oncology - Research Funding